Prolactin May Not Play a Role in Primary Antiphospholipid (Hughes') Syndrome
Table 2
Comparison between primary antiphospholipid syndrome patients (pAPS) with hyperprolactin and normal PRL levels.
pAPS with HPRL
pAPS with Normoprolactinemia
Age (years)
34
42
.053
Female gender, (%)
5 (100)
42 (84)
1.00
Caucasian race, (%)
3 (60)
46 (92)
.086
Disease duration, months
106 (27–189)
82 (1–224)
.279
Weight, kg
70 (57–90)
75 (47–156)
.237
Height, cm
161 (158–168)
162 (140–180)
.215
BMI, kg/cm2
27 (22.3–31.9)
26.75 (27.5–42.2)
.328
Waist, cm
81 (76–110)
91 (65–157)
.294
Sedentarism, (%)
5 (100)
29 (58)
.144
Current smoking, (%)
0
8 (16)
1.00
Previous smoking, (%)
0
20 (40)
.147
Arterial event, (%)
3 (60)
34 (68)
1.00
Venous event, (%)
2 (40)
28 (56)
.649
Obstetric event, (%)
1 (20)
21 (42)
.638
Stroke, (%)
2 (40)
22 (44)
1.00
Sneddon syndrome, (%)
0
11 (22)
.571
Limb ischemia, (%)
2 (40)
6 (12)
.149
Systemic arterial hypertension, (%)
1 (20)
23 (46)
.373
Acute Myocardial Infarction, (%)
0
1 (2)
1.00
Angina, (%)
0
7 (14)
1.00
Deep venous thrombosis, (%)
2 (40)
23 (46)
1.00
Pulmonary thromboembolism, (%)
1 (20)
9 (18)
1.00
Thrombocytopenia, (%)
0
12 (24)
.574
CRP, mg/L
0.87 (0.64–19)
3.22 (0.3–17.1)
.494
ESR, mm/1st hour
8.1 (2–32)
9 (2–58)
.287
Lupus anticoagulant, (%)
3 (60)
34 (68)
1.00
Anticardiolipin IgM, (%)
1 (20)
9 (18)
1.00
Anticardiolipin IgG, (%)
2 (40)
18 (36)
1.00
Warfarin use, (%)
4 (80)
46 (92)
.391
Chloroquine use, (%)
3 (60)
23 (46)
.659
Statin use, (%)
1 (20)
17 (34)
1.00
Acetylsalicylic acid use, (%)
2 (40)
29 (58)
.643
Data are presented as means (range or percentages); Mann-Whitney and Fischer tests were used. HPRL was defined as ng/mL for men and >15 ng/mL for women.
